A systematic review including 9 studies with a total of 11,015 subjects was abstracted in DARE. Patients receiving macrolide antibiotics showed no statistically significant reduction in cardiac events or mortality relative to those on placebo; the relative risks were 0.94 (95% CI: 0.86 to 1.03) and 0.94 (95% CI: 0.79 to 1.12) for cardiac events and mortality, respectively.
Comment: The quality of evidence is downgraded by the results being (statistically nonsignificantly) in favour of antibiotics.